Growth inhibition of human in vitro and mouse in vitro and in vivo mammary tumor models by retinoids in comparison with tamoxifen and the RU-486 anti-progestagen

Breast Cancer Research and Treatment

Volumn 51, Issue 1, 1998, Pages 39-55

  Darro, Francis ^a,b   Cahen, Pierre ^a,b   Vianna, Alexandre ^a,d   Decaestecker, Christine ^a   Nogaret, Jean Marie ^c   Leblond, Bertrand ^b   Chaboteaux, Carole ^a   Ramos, Cinthia ^a,d   Pétein, Michel ^c   Budel, Vinicius ^d   Schoofs, Alain ^b   Pourrias, Bernard ^b   Kiss, Robert ^a,e,f  

^a UNIVERSITÉ LIBRE DE BRUXELLES   (Belgium)

^b Ctr Europ de Bioprospective   (France)

^c JULES BORDET INSTITUTE   (Belgium)

^d FEDERAL UNIVERSITY OF PARANÁ   (Brazil)

^e FNRS   (Belgium)

^f FREE UNIVERSITY OF BRUSSELS   (Belgium)

Author keywords

Apoptosis; Human; Mammary tumor; Mouse; Proliferation; Retinoids; RU 486; Tamoxifen

Indexed keywords

ANTIESTROGEN; ANTIGESTAGEN; BENZOIC ACID DERIVATIVE; BEXAROTENE; FENRETINIDE; MIFEPRISTONE; RETINOIC ACID RECEPTOR; RETINOID; RETINOID X RECEPTOR; TAMOXIFEN;

ANCHORAGE INDEPENDENT GROWTH; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BREAST CARCINOMA; BREAST TUMOR; CANCER INHIBITION; CELL PROLIFERATION; CONTROLLED STUDY; HORMONE SENSITIVITY; HUMAN; HUMAN CELL; INTRAPERITONEAL DRUG ADMINISTRATION; MOUSE; NONHUMAN; PRIORITY JOURNAL;

ANIMALS; ANTICARCINOGENIC AGENTS; APOPTOSIS; BENZOATES; BREAST NEOPLASMS; CELL DIVISION; DISEASE MODELS, ANIMAL; FEMALE; FENRETINIDE; HORMONE ANTAGONISTS; HUMANS; MAMMARY NEOPLASMS, ANIMAL; MICE; MICE, INBRED C57BL; MIFEPRISTONE; RETINOIDS; TAMOXIFEN; TETRAHYDRONAPHTHALENES; TRETINOIN; TUMOR CELLS, CULTURED;

EID: 7844246539     PISSN: 01676806     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1006098124087     Document Type: Article

References (60)

1. Fisher B, Osborne CK, Margolese R, Bloomer W: Neoplasms of the breast. In: Holland JF, Frei E III, Bast RC Jr, Kufe DW, Morton DL, Weichselbaum RR (eds) Cancer Medicine. Lea & Febiger, Philadelphia - London, Volume 1, 1993, pp 1706-1774
2. Beatson GT: On the treatment of inoperable cases of carcinoma of the mamma. Suggestion for a new method of treatment with illustrative cases. Lancet 2: 104-107, 1896
3. Paridaens R, Leclercq G, Piccart M, Kiss R, Mattheiem W, Heuson JC: Comments on the treatment of breast cancer. In: Bulbrook RD (ed) Hormones of Cancer: 90 Years after Beatson. Cancer Surveys 5, 1986, pp 447-461
4. Costa A, Sacchini V, Decensi A: Retinoids and tamoxifen in breast cancer chemoprevention. Int J Clin Lab Res 23: 53-55, 1993
5. Anzano MA, Byers SW, Smith JM, Peer CM, Mullen LT, Brown CC, Roberts AB, Sporn MB: Prevention of breast cancer in the rat with 9-cis-retinoic acid as a single agent and in combination with tamoxifen. Cancer Res 54: 4614-4617, 1994
6. Gottardis MM, Bischoff ED, Shirley MA, Wagoner MA, Lamph WW, Heyman RA: Chemoprevention of mammary carcinoma by LGD1069 (Targretin): an RXR-selective ligand. Cancer Res 56: 5566-5570, 1996
7. Cassano E, Coopmans de Yoldi G, Ferranti C, Costa A, Mascotti G, De Palo G, Veronesi U: Mammographic patterns in breast cancer chemoprevention with Fenretinide (4-HPR). Eur J Cancer 29A: 2161-2163, 1993
8. Gottardis MM, Lamph WW, Shalinsky DR, Wellstein A, Heyman RA: The efficacy of 9-cis-retinoic acid in experimental models of cancer. Breast Cancer Res Treat 38:85-96, 1996
9. Dawson MI, Chao WR, Pine P, Jong L, Hobbs PD, Rudd CK, Quick TC, Niles RM, Zhang XK, Lombardo A, Ely KR, Shroot B, Fontana JA: Correlation of retinoic binding affinity to retinoic acid receptor α with retinoid inhibition of growth of estrogen receptor-positive MCF-7 mammary carcinoma cells. Cancer Res 55: 4446-4451, 1995
10. Shao ZM, Dawson MI, Li XS, Rishi AK, Sheikh MS, Han QX, Ordonez JV, Shroot B, Fontana JA: p53 independent G0/G1 arrest and apoptosis induced by a novel retinoid in human breast cancer cells. Oncogene 11: 493-504, 1995
11. James SY, Mackay AG, Colston KW: Vitamin D derivatives in combination with 9-cis-retinoic acid promote active cell death in breast cancer cells. J Mol Endocrinol 14: 391-394, 1995
12. Fanjul AN, Bouterfa H, Dawson M, Pfahl M: Potential role for retinoic acid receptor γ in the inhibition of breast cancer cells by selective retinoids and interferons. Cancer Res 56: 1571-1577, 1996
13. Liu Y, Lee MO, Wang HG, Li Y, Hashimoto Y, Klaus M, Reed JC, Zhang X: Retinoic acid receptor β mediates the growth-inhibitory effect of retinoic acid by promoting apoptosis in human breast cancer cells. Mol Cell Biol 16: 1138-1149, 1996
14. Lotan R: Retinoids in cancer chemoprevention. FASEB J 10: 1031-1039, 1996
15. Chambon P: A decade of molecular biology of retinoic acid receptors. FASEB J 10: 940-954, 1996
16. Urbach J, Rando RR: Isomerization of all-trans-retinoic acid to 9-cis-retinoic acid. Biochem J 299: 459-465, 1994
17. Boehm MF, Zhang L, Badea BA, White SK, Mais DE, Berger E, Suto CM, Goldman ME, Heyman RA: Synthesis and structure-activity relationship of novel retinoid X receptor-selective retinoids. J Med Chem 37: 2930-2941, 1994
18. Beard RL, Gil DW, Marler DK, Henry E, Colon DF, Gillett SJ, Arefieg T, Breen TS, Krauss H, Davies PJA, Chandraratna RAS: Structural basis for the differential RXR and RAR activity of stilbene retinoid analogs. Biorg Med Chem Lett 4: 1447-1452, 1994
19. Pellegrini R, Mariotti A, Tagliabue E, Bressan R, Bunone G, Coradini D, Della Valle G, Formelli F, Cleris L, Radice P, Pierotti MA, Colnghi MI, Ménard S: Modulation of markers associated with tumor aggressiveness in human breast cancer cell lines by N-(4-hydroxyphenyl) retinamide. Cell Growth Differ 6: 863-869, 1995
20. Kizaki M, Dawson MI, Heyman R, Elster E, Morosetti R, Pakkala S, Chen DL, Ueno H, Chao W, Morikawa M, Ikeda Y, Heber D, Pfahl M, Koeffler HP: Effects of novel retinoid X receptor-selective ligands on myeloid leukemia differentiation and proliferation in vitro. Blood 87: 1977-1984, 1996
21. Beck CA, Zhang Y, Weigel NL, Edwards DP: Two types of anti-progestins have distinct effects on site-specific phosphorylation of human progesterone receptor. J Biol Chem 271: 1209-1217, 1996
22. Watson CS, Medina D, Clark JH: Estrogen receptor characterization in a transplantable mouse mammary tumor. Cancer Res 37: 3344-3348, 1977
23. Danguy A, Kiss R, Leclercq G, Heuson JC, Pasteels JL: Morphology of MXT mouse mammary tumors. Correlation with growth characteristics and hormone sensitivity. Eur J Cancer Clin Oncol 22: 69-76, 1986
24. Kiss R, de Launoit Y, Danguy A, Paridaens R, Pasteels JL: Influence of pituitary grafts or prolactin administrations on the hormone sensitivity of ovarian hormone-independent mouse mammary MXT tumors. Cancer Res 49: 2945-2951, 1989
25. Briand P: Hormone-dependent mammary tumors in mice and rats as a model for human breast cancer (review). Anticancer Res 3: 273-282, 1983
26. Fingert HJ, Campisi J, Pardee AB: Cancer biology. Cell proliferation and differentiation. In: Holland JF, Frei E III, Bast RC Jr, Kufe DW, Morton DL, Weichselbaum RR (eds) Cancer Medicine. Lea & Febiger, Philadelphia - London, Volume 1, 1993, pp 1-14
27. Piacentini M, Fesus L, Farrace MG, Ghibelli L, Piredda L, Melino G: The expression of 'tissue' transglutaminase in two human cancer cell lines is related with the programmed cell death (apoptosis). Eur J Cell Biol 54: 246-254, 1991
28. Horn V, Minucci S, Ogryzko VV, Adamson ED, Howard BH, Levein AA, Ozato K: RAR and RXR selective ligands cooperatively induce apoptosis and neuronal differentiation in P19 embryonal carcinoma cells. FASEB J 10: 1071-1077, 1996
29. Salmon I, Kiss R: Relationship between proliferative activity and ploidy level in a series of 530 human brain tumors including astrocytomas, meningiomas, schwannomas and metastases. Human Pathol 24: 329-335, 1993
30. Freake HC, Marcocci C, Iwasaki J, MacIntyre I: 1,25-dihydroxyvitamin D3 specifically hinds to a human breast cancer cell line (T47D) and stimulates growth. Biochem Biophys Res Commun 101 (4): 1131-1138, 1981
31. Camby I, Salmon I, Danguy A, Pasteels JL, Brotchi J, Martinez J, Kiss R: Influence of gastrin on human astrocytic tumor cell proliferation. J Natl Cancer Inst 88: 594-600, 1996
32. Janssen T, Darro F, Petein M, Raviv G, Pasteels JL, Kiss R, Schulman C: In vitro characterization of prolactin-induced effects on proliferation in the neoplastic LNCaP, DU145 and PC3 models of the human prostate. Cancer 77: 144-149, 1996
33. Mosman T: Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxic assay. J Immunol Meth 65: 55-63, 1983
34. Vistica DT, Skehan P, Scudiero D, Monks A, Pittman A, Boyd MR: Tetrazolium-based assays for cellular viability: a critical examination of selected parameters affecting formazan production. Cancer Res 51: 2515-2525, 1991
35. Rubinstein LV, Shoemaker RH, Paull KD, Simon RM, Tosini S, Skehan P, Scudiero DA, Monks A, Boyd MR: Comparison of in vitro anticancer-drug-screening data generated with tetrazolium assay versus a protein assay against a diverse panel of human tumor cell lines. J Natl Cancer Inst 82: 1113-1118, 1990
36. Kiss R, Salmon I, Camby I, Gras S, Pasteels JL: Characterization of factors in routine laboratory protocols that significantly influence the Feulgen reaction. J Histochem Cytochem 41: 935-945, 1993
37. Lowry OH, Rusebrough NJ, Farr AL, Randall RJ: Protein measurement with the Folin phenol reagent. J Biol Chem 193: 265-275, 1951
38. Darzynkiewicz Z, Bruno S, Del Bino G, Gorczyca W, Hotz MA, Lassota P, Traganos F: Features of apoptotic cells measured by flow cytometry. Cytometry 13: 795-808, 1992
39. Ponzoni M, Bocca P, Chiesa V, Decensi A, Pistoia V, Raffaghello L, Rozzo C, Montaldo PG: Differential effects of N-(4-hydroxyphenyl)retinamide and retinoic acid on neuroblastoma cells: apoptosis versus differentiation. Cancer Res 55: 853-861, 1995
40. Sporn MB, Newton DL: Chemoprevention of cancer with retinoids. Fed Proc 38: 2528-2534, 1979
41. Jing Y, Zhang J, Waxman S, Mira Y, Lopez R: Upregulation of cytokeratins 8 and 18 in human breast cancer T-47D cells is retinoid-specific and retinoic acid receptor-dependent. Differentiation 60: 109-117, 1996
42. Van Der Leede BM, Geertzema J, Vroom TM, Decimo D, Lutz Y, Van Der Saag PT, Van Der Burg B: Immunohistochemical analysis of retinoic acid receptor-alpha in human breast tumors: retinoic acid receptor-alpha expression correlates with proliferative activity. Am J Pathol 148: 1905-1914, 1996
43. Wang TT, Phang JM: Effect of N-(4-hydroxyphenyl)retinamide on apoptosis in human breast cancer cells. Cancer Lett 107: 65-71, 1996
44. Fanjul AN, Delia D, Pierotti MA, Rideout D, Yu JQ, Pfahl M: 4-hydroxyphenyl retinamide is a highly selective activator of retinoid receptors. J Biol Chem 271 (37): 22441-22446, 1996
45. Kazmi SM, Plante RK, Visconti V, Lau CY: Comparison of N-(4-hydroxyphenyl)retinamide and all-trans-retinoic acid in the regulation of retinoid receptor-mediated gene expression in human breast cancer cell lines. Cancer Res 56: 1056-1062, 1996
46. Oridate N, Suzuki S, Higuchi M, Mitchell MF, Hong WK, Lotan R: Involvement of reactive oxygen species in N-(4-hydroxyphenyl)retinamide-induced apoptosis in cervical carcinoma cells. J Natl Cancer Inst 89 (16): 1191-1198, 1997
47. Standeven AM, Johnson AT, Escobar M, Chandraratna RA: Specific antagonist of retinoid toxicity in mice. Toxicol Appl Pharmacol 138: 169-175, 1996
48. Paridaens RJ, Danguy AJ, Leclercq G, Kiss R, Heuson JC: Effect of castration and 17 β-estradiol pulse on cell proliferation in the uterus and the MXT mouse mammary tumor. J Natl Cancer Inst 74: 1239-1246, 1985
49. Harris J, Morrow M, Norton L: Cancer of the breast (Chapter 36). Malignant tumors of the breast (Section 2). In: De Vita VT Jr, Hellman S, Rosenberg SA (eds) Cancer: Principles and Practice of Oncology. Fifth Edition. JB Lippincott Co., Philadelphia, 1997, pp 1557-1616
50. Pollack IF, Kawecki S: The efficacy of tamoxifen as an anti-proliferative agent in vitro for benign and malignant pediatric glial tumors. Pediatric Surg 22: 281-288, 1995
51. Couldwell WT, Hinton DR, He S, Chen TC, Sebat I, Weiss MH, Law RE: Protein kinase C inhibitors induce apoptosis in human malignant glioma cell lines. FEBS Lett 345: 43-46, 1994
52. Berry J, Green BJ, Matheson DS: Modulation of natural killer cell activity by tamoxifen in stage I post-menopausal breast cancer. Eur J Cancer Clin Oncol 23: 517-520, 1987
53. Gottardis MM, Wagner RJ, Borden EC, Jordan VC: Differential ability of antiestrogens to stimulate breast cancer cell (MCF-7) growth in vitro and in vivo. Cancer Res 49: 4765-4769, 1989
54. Szende B, Schally AV, Comaru-Schally AM, Redding TW, Srkalovic G, Groot K, Lapis K, Timar J, Neill J, Mulchahey J: Cellular and molecular aspects of apoptosis in experimental tumors of animals treated with analogs of LHRH and somatostatin. In: Tomei LD, Cope FO (eds) Apoptosis: The Molecular Basis of Cell Death. Cold Spring Laboratory Press, 1991, pp 139-155
55. Allegretto EA, McClurg MR, Lazarchik SB, Clemm DL, Kerner SA, Elgort MG, Boehm MF, White SK, Pike JW, Heyman RA: Transactivation properties of retinoic acid and retinoid X receptors in mammalian cells and yeast. J Biol Chem 258: 26625-26633, 1993
56. Pignatello MA, Kauffman FC, Levin AA: Multiple factors contribute to the toxicity of the aromatic retinoid, TTNPB (Ro 13-7410): binding affinities and disposition. Toxicol Appl Pharmacol 142: 319-327, 1997
57. Gottardis MM, Bischoff ED, Shirley MA, Wagoner MA, Lamph WW, Heyman RA: Chemoprevention of mammary carcinoma LGD1069 (targretin): an RXR-selective ligand. Cancer Res 56: 5566-5570, 1996
58. Sheikh MS, Zhao Z-M, Li X-S, Ordonez JV, Conley BA, Wu S, Dawson MJ, Han Q-X, Chao W-R, Quick T, Niles RM, Fontana JA: N-(4-hydroxyphenyl)retinamide (4-HPR)-mediated biological actions involve retinoid receptor-independent pathways in human breast carcinoma. Carcinogenesis 16: 2477-2486, 1995
59. Viljoen TC, van Aswegen CH, du Plessis DJ: Binding of estradiol to whole prostatic DU-145 cells in the presence and absence of tamoxifen and acetylsalicylic acid. Prostate 27: 160-165, 1995
60. Terakawa N, Shimizu I, Tanizawa O, Matsumoto K: RU486, a progestin antagonist, binds to progesterone receptors in a human endometrial cancer cell line and reverses the growth inhibition by progestins. J Steroid Biochem 31: 161-166, 1988